Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Coherus Oncology, Inc. (CHRS) has a Wall Street consensus price target of $6.02, based on estimates from 16 covering analysts. With the stock currently trading at $1.67, this represents a potential upside of +260.5%. The company has a market capitalization of $194M.
Analyst price targets range from a low of $1.05 to a high of $11.00, representing a 165% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CHRS trades at a trailing P/E of 6.7x. Analysts expect EPS to grow -184.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $-0.28, with bear and bull scenarios of $-234.27 and $0.52 respectively. Model confidence stands at 21/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CHRS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for CHRS is $6.02, representing 260.5% upside from the current price of $1.67. With 16 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CHRS has a consensus rating of "Buy" based on 16 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $6.02 implies 260.5% upside from current levels.
CHRS's current price is $1.67 with a consensus target of $6.02 (260.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $11 for CHRS, while the most conservative target is $1.05. The consensus of $6.02 represents the median expectation. Our quantitative valuation model projects a bull case target of $1 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CHRS is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHRS stock forecast based on 16 Wall Street analysts shows a consensus price target of $6.02, with estimates ranging from $1.05 (bear case) to $11 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $-0, with bear/bull scenarios of $-234/$1.
Our quantitative valuation model calculates CHRS's fair value at $-0 (base case), with a bear case of $-234 and bull case of $1. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 21/100.
Wall Street analysts are very optimistic on CHRS, with a "Buy" consensus rating and $6.02 price target (260.5% upside). 13 of 16 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHRS analyst price targets range from $1.05 to $11, a 165% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.02 consensus represents the middle ground. Our model's $-234-$1 range provides an independent fundamental perspective.